Firms May Revise Labeling Without FDA Okay Only When New Safety Data Emerges
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA issues proposed rule that bolsters preemption defense of drug and device manufacturers in product liability litigation.
You may also be interested in...
FDA Finalizes Labeling Rule As Pre-emption Battle At Supreme Court Looms
January’s proposed rule remains mostly unchanged, but the definition of “newly acquired information” is slightly broader now.
FDA Finalizes Labeling Rule As Pre-emption Battle At Supreme Court Looms
January’s proposed rule remains mostly unchanged, but the definition of “newly acquired information” is slightly broader now.
FDA Pre-emption Wins On Appeal, But Coming Supreme Court Case May Mean More For Drug Liability Risks
Third Circuit Court of Appeals tosses failure-to-warn claims against GSK and Pfizer.